O.K. I don't like forums, but I came across this one and had to respond to this one. I have been getting Chiropractic treatment for the last 5 years - I even worked for one for over a year - one just like you referred too. A Life or Body by God type Chiropractor - the belief is that by keeping your spine free of subluxation your body then has the ability to heal and keep itself well the way God designed your body to do. Chiropractic FIRST, Medicine SECOND and Surgery LAST……
I do feel for your loss it is always hard to loose someone you love, but, did you ever stop to research how long he lived BECAUSE of his Chiropractic treatment? That while he died at 79 his last few years did not involve tests, chemo, radiation and a total lack of a quality life? If not for Chiropractic he may have gotten his cancer at a much younger age, it may have spread much more quickly, and he could have died much younger?
While writing this I did some research to see four things: the causes and symptoms of bladder cancer, the treatment, and the survival rate. Some of those findings are included at the end… there are not many symptoms, and if he did not tell his Chiropractor that he had blood in his urine, the Chiropractor would have had no way to tell that something was wrong with him, it is each persons responsibility to disclose symptoms and to go to the appropriate doctor. I wouldn’t go to my Chiropractor if my Appendix was infected.
Incidence of bladder cancer increases with age. People over the age of 70 develop the disease 2 to 3 times more often than those aged 55–69 and 15 to 20 times more often than those aged 30–54.
Bladder cancer is 2 to 3 times more common in men. In the United States, approximately 38,000 men and 15,000 women are diagnosed with the disease each year. Bladder cancer is the fourth most common type of cancer in men and the eighth most common type in women. The disease is more prevalent in Caucasians than in African Americans and Hispanics.
Causes and Risk Factors
Bladder cancer, considered a worldwide problem, is a leading tobacco-related cancer. In the United States, it is the fourth most common cancer in men and the eighth in women. According to the American Cancer Society, approximately 57,000 people are expected to be diagnosed with bladder cancer in this country in 2003 and an estimated 12,500 people will die of the disease.
• Chronic bladder inflammation (recurrent urinary tract infections, urinary stones)
• Consumption of Aristolochia fangchi (herb used in some weight-loss formulas)
• Diet high in saturated fat
• Exposure to second-hand smoke
• External beam radiation
• Family history of bladder cancer (several genetic risk factors identified)
• Gender (male)
• Infection with Schistosoma haematobium ( parasite found in many developing countries)
• Personal history of bladder cancer
• Race (Caucasian)
• Treatment with certain drugs (e.g., cyclophosfamide—used to treat cancer)
Signs and Symptoms
The primary symptom of bladder cancer is blood in the urine (hematuria). Hematuria may be visible to the naked eye (gross) or visible only under a microscope (microscopic) and is usually painless. Other symptoms include frequent urination and pain upon urination (dysuria).
Because of its tendency to spread, researchers have investigated a number of therapies to treat transitional cell bladder cancer (the most common form of the disease) which has invaded the bladder muscle and, therefore, is considered locally advanced. Studies to date have found that radiation therapy before surgery did not improve outcome.
With chemotherapy proving beneficial in patients with bladder cancer that had spread to other organs, SWOG began a randomized study in 1987 testing survival in patients who received surgery alone, versus patients treated with a three cycles of a chemotherapy combination known as M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) before surgery. The study included 126 institutions around the country.
In all, 154 patients were assigned to receive surgery as primary treatment, and 153 patients received combination therapy. At the end of the study, researchers found that median survival between the two groups was significantly different. Patients treated with surgery lived a median of 41 months, compared to 77 months in patients treated with chemotherapy followed by surgery.
When the investigators looked at death rates from bladder cancer, they concluded that more patients treated with surgery alone died of the disease, and they died at a faster rate –– 77 patients died of bladder cancer in the surgery arm, compared to 54 in the combination treatment group. Patients treated with surgery alone had a 66 percent greater risk of dying from bladder cancer than patients who received neoadjuvant chemotherapy, according to the research team.
When overall death rates were considered –– death from any cause, not just bladder cancer –– the results were not as significant, Grossman says. After follow-up of more than eight years in each group, 90 deaths occurred in the combination therapy compared with 100 deaths in the group treated with surgery, meaning that patients who received surgery had a 33 percent greater chance of dying than patients treated with combination therapy, says Grossman. "These patients are generally older and may die of other causes, but the chance of surviving was higher in the neoadjuvant group," he says.
Patients who did best of all were those who had no cancer left in the bladder at the time of surgery, the researchers concluded. At the time of surgery, significantly more patients (38 percent) had no evidence of cancer remaining in bladder tissue, compared to 15 percent of patients who did not have prior chemotherapy.
"There were significantly more patients in the neoadjuvant group who had no residual disease compared to the surgery group and those are the patients that have much better survival. The chemotherapy effectively down-staged their cancer," says Grossman. "Ten years after treatment, some of those patients are still alive, so neoadjuvant chemotherapy before surgery provided a cure for them."